CL2023001215A1 - Formulación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso de preparación - Google Patents

Formulación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso de preparación

Info

Publication number
CL2023001215A1
CL2023001215A1 CL2023001215A CL2023001215A CL2023001215A1 CL 2023001215 A1 CL2023001215 A1 CL 2023001215A1 CL 2023001215 A CL2023001215 A CL 2023001215A CL 2023001215 A CL2023001215 A CL 2023001215A CL 2023001215 A1 CL2023001215 A1 CL 2023001215A1
Authority
CL
Chile
Prior art keywords
oral formulation
indol
pyrazole
cyano
isopropyl
Prior art date
Application number
CL2023001215A
Other languages
English (en)
Spanish (es)
Inventor
Sun Lee
Seok Cheol Yoo
Duck Il Yun
Junghong Park
Hyun Ji Sun
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2023001215A1 publication Critical patent/CL2023001215A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2023001215A 2020-12-01 2023-04-27 Formulación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso de preparación CL2023001215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01

Publications (1)

Publication Number Publication Date
CL2023001215A1 true CL2023001215A1 (es) 2023-12-15

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001215A CL2023001215A1 (es) 2020-12-01 2023-04-27 Formulación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso de preparación

Country Status (15)

Country Link
US (1) US20240000751A1 (cg-RX-API-DMAC7.html)
EP (1) EP4257123A4 (cg-RX-API-DMAC7.html)
JP (1) JP7678106B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220077091A (cg-RX-API-DMAC7.html)
CN (1) CN116528852B (cg-RX-API-DMAC7.html)
AR (1) AR124178A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021390901B9 (cg-RX-API-DMAC7.html)
CA (1) CA3197405A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001215A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008265A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023005459A (cg-RX-API-DMAC7.html)
PE (1) PE20240222A1 (cg-RX-API-DMAC7.html)
TW (3) TW202600130A (cg-RX-API-DMAC7.html)
WO (1) WO2022119269A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305156B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901895B (zh) * 2021-06-15 2025-10-21 南韓商Lg化學股份有限公司 一種包含1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-甲酸的醫藥組成物
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538102A (ja) * 2002-07-31 2005-12-15 ファルマシア・コーポレーション 低下された架橋を示すゼラチンカプセル
WO2006078948A2 (en) * 2005-01-21 2006-07-27 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of zonisamide and methods for their manufacture
CN101679251B (zh) * 2007-04-11 2013-10-02 橘生药品工业株式会社 (氮杂)吲哚衍生物及其医药用途
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Lg生命科學有限公司 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶型及其製造方法
WO2020109319A1 (en) * 2018-11-27 2020-06-04 Zaklady Farmaceutyczne Polpharma S.A Pharmaceutical composition comprising ramipril and indapamide
CA3194595A1 (en) * 2020-11-04 2022-05-12 Seok Ju Lee Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
PE20230850A1 (es) * 2020-12-01 2023-05-23 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
PE20240764A1 (es) * 2021-04-16 2024-04-17 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico

Also Published As

Publication number Publication date
CA3197405A1 (en) 2022-06-09
AU2024227367A1 (en) 2024-10-31
PE20240222A1 (es) 2024-02-16
JP2023551712A (ja) 2023-12-12
MX2023005459A (es) 2023-05-23
TW202600130A (zh) 2026-01-01
TWI840721B (zh) 2024-05-01
EP4257123A4 (en) 2024-05-08
US20240000751A1 (en) 2024-01-04
AU2021390901A9 (en) 2024-05-23
TWI896975B (zh) 2025-09-11
WO2022119269A1 (ko) 2022-06-09
EP4257123A1 (en) 2023-10-11
ZA202305156B (en) 2024-09-25
TW202408496A (zh) 2024-03-01
AU2021390901A1 (en) 2023-06-08
AR124178A1 (es) 2023-02-22
KR20220077091A (ko) 2022-06-08
TW202228679A (zh) 2022-08-01
JP7678106B2 (ja) 2025-05-15
AU2021390901B2 (en) 2024-11-07
AU2021390901B9 (en) 2024-11-21
CO2023008265A2 (es) 2023-06-30
CN116528852A (zh) 2023-08-01
CN116528852B (zh) 2026-05-12

Similar Documents

Publication Publication Date Title
CO2023008265A2 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
EA201490801A1 (ru) Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов
CY1124690T1 (el) Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη
EP4613741A3 (en) Lipid nanoparticles for oligonucleotide delivery
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JOP20250145A1 (ar) صيغ لتركيبات لقاح فيروس حُمى الضنك
CY1115526T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
ZA202403337B (en) Lipid nanoparticles for oligonucleotide delivery
MX354073B (es) Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico.
MX2019007239A (es) Nueva formulacion que comprende un derivado de bencimidazol.
PH12018500458A1 (en) Vlp stabilized vaccine compositions
JOP20220355A1 (ar) مثبطات rip1k
MX2017015812A (es) Formulaciones farmaceuticas inyectables de lefamulina.
MX380172B (es) Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.
MX390374B (es) Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo]
JOP20250189A1 (ar) تركيبة قابلة للحقن ومستحضر صيدلاني يحتوي عليها وطريقة تحضيرها
CL2023001061A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación.
MX2025006079A (es) Composicion de insulina de accion rapida (variantes)
ZA202203563B (en) Pediatric suspension formulation
WO2022131880A3 (ko) 2종 이상의 서로 다른 조성물을 함유한 제제학적으로 안정한 연질캡슐제
WO2021245700A3 (en) Pharmaceutical lipid compositions of remdesivir
WO2022157747A3 (en) Pharmaceutical glp peptide compositions and methods of preparation thereof
CL2023003571A1 (es) Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
MX393290B (es) Composicion para el tratamiento de la osteoartritis